Clinical trials · Georgia
Relapsed/Refractory Multiple Myeloma clinical trials in Georgia
We’re tracking 8 recruiting relapsed/refractory multiple myeloma studies with a site in Georgia — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Georgia
- NCT04973605RecruitingPhase 1/Phase 2
Sonrotoclax with steroid and other drugs for multiple myeloma
This early-phase study tests sonrotoclax (a cancer medicine) in people with multiple myeloma that has come back or not responded to prior treatment. It also studies different combinations with dexamethasone plus other standard medicines, aiming to shrink tumors and improve control of the disease.
Atlanta, GeorgiaAges 18 years+ - NCT05850234RecruitingPhase 1/Phase 2
Study drug for hard-to-treat multiple myeloma after prior treatments
This Phase 1/2 study tests AZD0120 in people with multiple myeloma that has come back or is not responding to treatment. It may help by targeting the myeloma cells after you’ve already tried several standard therapies.
Atlanta, GeorgiaAges 18 years+ - NCT07284758RecruitingPhase 2
Cemsidomide and dexamethasone for relapsed/refractory multiple myeloma
This clinical trial tests a new combination of two medicines (cemsidomide and dexamethasone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new drug can help control the cancer when other options have stopped working.
Atlanta, GeorgiaAges 18 years+ - NCT07222761RecruitingPhase 3
Comparing new treatments for relapsed multiple myeloma
This trial tests if a new medicine called linvoseltamab, alone or combined with carfilzomib, works better than the usual treatments for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies.
Atlanta, GeorgiaAges 18 years+ - NCT07280013RecruitingPhase 1
Cemsidomide with elranatamab for multiple myeloma
This trial tests a new drug combination (cemsidomide and elranatamab) for people with multiple myeloma that has come back after previous treatments. The goal is to see if the combination is safe and works better than current options.
Atlanta, GeorgiaAges 18 years+ - NCT05862012RecruitingPhase 1
Test drug ISB 2001 in multiple myeloma patients who relapsed
This Phase 1 study tests ISB 2001, a new investigational treatment, in people with multiple myeloma that has come back or not responded to prior treatment. It mainly focuses on safety and whether the drug can be given effectively.
Atlanta, GeorgiaAges 18 years+ - NCT06158841RecruitingPhase 3
Etentamig vs standard therapy for relapsed myeloma
This trial tests a new IV treatment called etentamig compared to standard therapies for people with multiple myeloma that has come back or stopped responding. It may be an option if you've already tried at least two different treatments, including common drug classes.
Atlanta, GeorgiaAges 18 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Atlanta, GeorgiaAges 18 years+
Relapsed/Refractory Multiple Myeloma trials by city in Georgia
Where these studies are running in Georgia
Institutions with a site for the recruiting relapsed/refractory multiple myeloma studies listed above.
- Emory University · 6 studies
- Augusta University Medical Center
- Blood and Marrow Transplant Group of Georgia
- Research Site
What taking part in a relapsed/refractory multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Relapsed/Refractory Multiple Myeloma trials in other states
Common questions
- Are there relapsed/refractory multiple myeloma clinical trials in Georgia?
- Yes. We're currently tracking 8 recruiting relapsed/refractory multiple myeloma studies with a site in Georgia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a relapsed/refractory multiple myeloma study in Georgia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Georgia to take part?
- Not necessarily. These studies have a site in Georgia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a relapsed/refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New relapsed/refractory multiple myeloma studies open in Georgia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.